Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.
The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.
Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.
The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.
Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.
In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.
Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.
For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.
Teleflex Incorporated (NYSE: TFX) has introduced an online submission portal for its COVID-19 Humanitarian Product Donation Program. The initiative aims to supply critical medical devices, including Personal Protective Equipment, to healthcare providers and patients battling COVID-19. Teleflex emphasizes that the program is strictly humanitarian, with no expectation of commercial gain. Donations will be reported to relevant governmental agencies to ensure transparency. For further details, interested parties can reach out via the provided email or visit the Teleflex website.
Teleflex (NYSE: TFX) has released data showing the superior efficacy of the UroLift® System for treating benign prostatic hyperplasia (BPH) compared to the Rezum™ steam injection. The study revealed that 93% of patients treated with UroLift were catheter-free by day three, compared to just 45% for Rezum. Additionally, 83% of UroLift patients expressed satisfaction with their treatment, versus 65% for Rezum. The UroLift System allows for rapid recovery and preservation of sexual function, highlighting its growing acceptance in urological care.
WAYNE, Pa., June 03, 2020 - Thomas Powell, CFO of Teleflex (NYSE: TFX), will present at the Raymond James 2020 Human Health Innovation Conference on June 17, 2020 at 2:20 p.m. ET. A live audio webcast of his presentation, along with slides, will be available on the Teleflex investor website.
Teleflex is a global medical technology provider focused on innovative solutions across various healthcare fields including vascular access, anesthesia, and emergency medicine.
Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in a pivotal clinical study evaluating the effectiveness of its coronary guidewires and specialty catheters in Chronic Total Occlusion (CTO) procedures. The CTO-PCI study aims to enroll up to 150 patients at roughly 15 sites across the US. The study will assess key metrics, including successful guidewire placement and major adverse cardiac events. The principal investigators from notable institutions emphasize the importance of this research in enhancing techniques for treating complex coronary blockages.
Teleflex announced the pricing of a private offering of $500 million in 4.25% senior notes due 2028, scheduled to close on May 27, 2020. The notes will be guaranteed by its wholly-owned domestic subsidiaries. Proceeds will be used to repay borrowings under its revolving credit facility. This offering is made under exemptions from the Securities Act of 1933, targeting qualified institutional buyers and certain non-U.S. persons. The notes have not been registered and cannot be sold in the U.S. without registration or exemption.
Teleflex has announced a private offering of $500 million in senior notes due 2028, subject to market conditions. These notes will be guaranteed by its wholly-owned subsidiaries. The proceeds will be used to repay borrowings from its revolving credit facility. This offering is targeted at qualified institutional buyers and non-U.S. persons outside the U.S. and will not be registered under the Securities Act.
On May 18, 2020, Teleflex presented data at the AUA 2020 Virtual Experience highlighting the UroLift® System’s benefits for treating benign prostatic hyperplasia (BPH). Studies demonstrated that the minimally invasive treatment significantly preserves sexual function compared to traditional medical therapies. In a meta-analysis involving 1,039 men, UroLift patients reported substantial improvements in ejaculatory and erectile function over 48 months. Additionally, a real-world study found equivalent safety profiles across patient groups, with 84% of urinary retention patients becoming catheter-independent post-treatment.
FAQ
What is the current stock price of Teleflex (TFX)?
What is the market cap of Teleflex (TFX)?
What does Teleflex Incorporated do?
Where is Teleflex Incorporated headquartered?
How many people does Teleflex employ?
What are the main segments of Teleflex's business?
What percentage of Teleflex’s revenue comes from the United States?
What recent acquisitions has Teleflex made?
What is the UroLift™ System?
What was Teleflex's revenue growth in 2023?
How can one access Teleflex's investor conference calls?
What is the mission of Teleflex Incorporated?
